Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Eye Contact Lens. 2010 Jul;36(4):210-4. doi: 10.1097/ICL.0b013e3181e4bb40.
The purpose of this study was to compare the efficacy of olopatadine with fluorometholone in contact lens-induced mild to moderate papillary conjunctivitis.
A randomized, double-masked study was conducted. Eighty-five (n = 170 eyes) soft contact lens users with mild to moderate papillary conjunctivitis were enrolled. Patients were randomly assigned to three groups to receive olopatadine 0.1%, fluorometholone 0.1%, or both. All drugs were instilled twice daily for 8 weeks. Contact lens use was discontinued during initial 4 weeks of therapy and subsequently patients were prescribed monthly disposable lenses. Patients were followed up every 2 weeks, and variables assessed were symptoms and signs, tear film status, and intraocular pressures.
Decrease in ocular redness, itching, and tearing along with improvement in contact lens tolerance was comparable in all the three groups. Olopatadine was more effective in reducing redness than fluorometholone at 8 weeks (P=0.01). Improvement in congestion and papillary reaction was comparable in all groups. There was a significant increase in tear break up time of more than 2 sec for fluorometholone and no significant increase for olopatadine. The olopatadine and fluorometholone groups had significant increase of more than 2 mm in Schirmer test and more than 3 sec in tear break up time. In patients with subnormal and borderline tear functions, significant improvement was observed with both drugs. After 8 weeks of use of fluorometholone, there was a significant increase in intraocular pressure (P=0.003).
Olopatadine and fluorometholone were the most effective for papillary conjunctivitis followed by olopatadine monotherapy and then fluorometholone monotherapy. Olopatadine is effective in alleviating signs and symptoms of contact lens-induced mild to moderate papillary conjunctivitis and is comparable with fluorometholone in efficacy.
本研究旨在比较奥洛他定和氟米龙治疗软性角膜接触镜引起的轻度至中度乳头性结膜炎的疗效。
进行了一项随机、双盲研究。纳入了 85 名（n=170 只眼）软性角膜接触镜使用者，他们患有轻度至中度乳头性结膜炎。患者被随机分为三组，分别接受奥洛他定 0.1%、氟米龙 0.1%或两者联合治疗。所有药物均每日滴眼 2 次，共 8 周。在治疗的最初 4 周内停止使用隐形眼镜，随后患者被开具每月一次性隐形眼镜。患者每 2 周随访一次，评估的变量包括症状和体征、泪膜状态和眼压。
所有三组的眼部红肿、瘙痒和流泪减少以及隐形眼镜耐受性改善情况相当。奥洛他定在 8 周时比氟米龙更有效地减轻眼红（P=0.01）。所有组的充血和乳头反应改善情况相当。氟米龙的泪膜破裂时间增加超过 2 秒，而奥洛他定则没有显著增加。奥洛他定和氟米龙组的 Schirmer 测试增加超过 2mm，泪膜破裂时间增加超过 3 秒。在泪液功能低下和边缘型的患者中，两种药物均观察到显著改善。使用氟米龙 8 周后，眼压显著升高（P=0.003）。
奥洛他定和氟米龙是治疗乳头性结膜炎最有效的药物，其次是奥洛他定单药治疗，然后是氟米龙单药治疗。奥洛他定可有效缓解软性角膜接触镜引起的轻度至中度乳头性结膜炎的症状和体征，其疗效与氟米龙相当。
